The Clinical and Pathological Characteristics That Differentiate Cases With "Low Estrogen Receptor Expression" From Triple-Negative Breast Cancer.

IF 1.3 Q4 ONCOLOGY
European journal of breast health Pub Date : 2023-12-27 eCollection Date: 2024-01-01 DOI:10.4274/ejbh.galenos.2023.2023-6-3
Cem Karaali, Mümin Emiroğlu, Mustafa Değirmenci, Murat Keser, Semra Salimoğlu, Canan Kelten Talu
{"title":"The Clinical and Pathological Characteristics That Differentiate Cases With \"Low Estrogen Receptor Expression\" From Triple-Negative Breast Cancer.","authors":"Cem Karaali, Mümin Emiroğlu, Mustafa Değirmenci, Murat Keser, Semra Salimoğlu, Canan Kelten Talu","doi":"10.4274/ejbh.galenos.2023.2023-6-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Estrogen receptor (ER) expression is an immunohistochemical marker that is examined in all invasive breast cancers and has prognostic and predictive value. ER-positive breast cancers refer to those that show positivity for ER at 1% cellular expression or higher. The American Society of Clinical Oncology/College of American Pathologists guidelines suggest using the term \"low ER-positive breast cancer\" for tumors with ER expression between 1% and 10%. Low ER-positive breast cancers exhibit similarities, in terms of disease-free survival and overall survival rates, to triple-negative breast cancers (TNBCs) rather than ER-positive breast cancers. In this study, our aim was to compare the clinicopathological characteristics of low ER-positive breast cancer cases diagnosed and followed in our clinic with TNBCs.</p><p><strong>Materials and methods: </strong>A total of 26 cases of low ER-positive breast cancer diagnosed at University of Health Sciences Turkey, İzmir Tepecik Training and Research Hospital between 2010 and 2016 were retrieved from hospital records. The relevant histopathology slides and blocks were retrieved and re-evaluated retrospectively through microscopic examination. Thirteen cases that met the criteria were included in the study. Additionally, a consecutive series of 13 TNBC cases that did not receive neoadjuvant treatment within the same time period were identified.</p><p><strong>Results: </strong>In the low ER-positive group, the presence of tumor necrosis, as well as histological grade, nuclear grade and Ki-67 proliferation index were significantly lower compared to the TNBC group. Ductal carcinoma <i>in situ</i> (DCIS) was significantly more common in the low ER-positive group compared to the TNBC group. There were no significant differences between the two groups in terms of tumor size, histological tumor type, axillary lymph node involvement, tumor margins, peritumoral and intratumoral inflammation, local recurrence, distant metastasis, survival, and other characteristics.</p><p><strong>Conclusion: </strong>Although our study consisted of a small number of cases, some features showed significant differences between low ER-positive breast cancers and TNBCs. Histological and nuclear grades, as well as the presence of a DCIS component, were associated with low ER-positive breast cancer. In contrast, the presence of tumor necrosis, as well as Grade 3 features and a high Ki-67 proliferation index indicated TNBC.</p>","PeriodicalId":93996,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765462/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of breast health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/ejbh.galenos.2023.2023-6-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Estrogen receptor (ER) expression is an immunohistochemical marker that is examined in all invasive breast cancers and has prognostic and predictive value. ER-positive breast cancers refer to those that show positivity for ER at 1% cellular expression or higher. The American Society of Clinical Oncology/College of American Pathologists guidelines suggest using the term "low ER-positive breast cancer" for tumors with ER expression between 1% and 10%. Low ER-positive breast cancers exhibit similarities, in terms of disease-free survival and overall survival rates, to triple-negative breast cancers (TNBCs) rather than ER-positive breast cancers. In this study, our aim was to compare the clinicopathological characteristics of low ER-positive breast cancer cases diagnosed and followed in our clinic with TNBCs.

Materials and methods: A total of 26 cases of low ER-positive breast cancer diagnosed at University of Health Sciences Turkey, İzmir Tepecik Training and Research Hospital between 2010 and 2016 were retrieved from hospital records. The relevant histopathology slides and blocks were retrieved and re-evaluated retrospectively through microscopic examination. Thirteen cases that met the criteria were included in the study. Additionally, a consecutive series of 13 TNBC cases that did not receive neoadjuvant treatment within the same time period were identified.

Results: In the low ER-positive group, the presence of tumor necrosis, as well as histological grade, nuclear grade and Ki-67 proliferation index were significantly lower compared to the TNBC group. Ductal carcinoma in situ (DCIS) was significantly more common in the low ER-positive group compared to the TNBC group. There were no significant differences between the two groups in terms of tumor size, histological tumor type, axillary lymph node involvement, tumor margins, peritumoral and intratumoral inflammation, local recurrence, distant metastasis, survival, and other characteristics.

Conclusion: Although our study consisted of a small number of cases, some features showed significant differences between low ER-positive breast cancers and TNBCs. Histological and nuclear grades, as well as the presence of a DCIS component, were associated with low ER-positive breast cancer. In contrast, the presence of tumor necrosis, as well as Grade 3 features and a high Ki-67 proliferation index indicated TNBC.

区分 "低雌激素受体表达 "与三阴性乳腺癌病例的临床和病理特征。
目的:雌激素受体(ER)表达是所有浸润性乳腺癌的免疫组化标记,具有预后和预测价值。ER阳性乳腺癌是指细胞ER表达阳性率达到或超过1%的乳腺癌。美国临床肿瘤学会/美国病理学家学会指南建议使用 "低ER阳性乳腺癌 "来描述ER表达在1%到10%之间的肿瘤。就无病生存率和总生存率而言,低ER阳性乳腺癌与三阴性乳腺癌(TNBC)而非ER阳性乳腺癌有相似之处。在这项研究中,我们的目的是比较在本诊所诊断和随访的低ER阳性乳腺癌病例与TNBC的临床病理特征:从医院记录中检索了土耳其健康科学大学伊兹密尔泰佩契克培训与研究医院在2010年至2016年期间诊断的26例低ER阳性乳腺癌病例。检索了相关的组织病理学切片和切块,并通过显微镜检查重新进行了评估。符合标准的 13 例病例被纳入研究。此外,研究还发现了同一时期未接受新辅助治疗的13例TNBC病例:结果:与TNBC组相比,低ER阳性组的肿瘤坏死、组织学分级、核分级和Ki-67增殖指数均明显较低。与TNBC组相比,低ER阳性组中乳腺导管原位癌(DCIS)的发生率明显更高。两组患者在肿瘤大小、肿瘤组织学类型、腋窝淋巴结受累、肿瘤边缘、瘤周和瘤内炎症、局部复发、远处转移、生存期和其他特征方面无明显差异:尽管我们的研究只涉及少量病例,但一些特征显示低ER阳性乳腺癌与TNBC之间存在显著差异。组织学和核分级以及是否存在 DCIS 成分与低 ER 阳性乳腺癌有关。相反,出现肿瘤坏死、3级特征和高Ki-67增殖指数则表示TNBC。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信